Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Acute Respiratory Failure-II

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:

Other Pulmonary Disorders

Other Pulmonary Disorders

Respiratory disorders encompass a range of conditions with varying levels of severity. Asthma, marked by chronic airway inflammation and hypersensitivity, is one such condition. It can lead to airway obstruction due to factors like bronchial spasms, mucosal edema, increased mucus secretion, or epithelial damage. Asthma triggers are diverse, ranging from allergens to emotional upset, and treatment focuses on both immediate relief through bronchodilators and long-term inflammation suppression.

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation

Acute Respiratory Failure-V

Acute Respiratory Failure-V

The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...

Acute Respiratory Failure-III

Acute Respiratory Failure-III

Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...

Rheumatic Heart Disease I: Introduction

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Pulmonary Alveolar Proteinosis in Greece-Türkiye-Cyprus: Answers in a Real-Life Comparison.

Respirology (Carlton, Vic.)·2026

Same author

Pulmonary fibrosis in chILD: bridging the gap.

The Lancet. Respiratory medicine·2026

Same author

Access to lymphangioleiomyomatosis care across Europe: an ERN-LUNG survey of clinical practice, and the case for a European registry and trial network.

ERJ open research·2026

Same author

Telomere length, common variants, and rare variants in IPF: a trio of key risk determinants.

The Lancet. Respiratory medicine·2026

Same author

Unmasking Early Cardiac Fibrosis in Sarcoidosis: The Role of Plasma Aldosterone and Cardiac MRI.

Journal of clinical medicine·2026

Same author

Clinical characteristics of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia.

ERJ open research·2026

Search research articles

Related Experiment Video

Updated: Mar 24, 2026

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

Acute Respiratory Events in Connective Tissue Disorders.

Spyros A Papiris¹, Effrosyni D Manali, Likurgos Kolilekas

¹2nd Department of Pneumonology, x2018;Attikon' University Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Respiration; International Review of Thoracic Diseases

|March 4, 2016

Summary

Acute respiratory events are a major cause of death in connective tissue disorders (CTDs). Managing these severe lung complications requires specialized multidisciplinary care to improve patient survival.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

Related Experiment Videos

Last Updated: Mar 24, 2026

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Mouse Model of Oleic Acid-Induced Acute Respiratory Distress Syndrome

Published on: June 2, 2022

Experimental Model to Evaluate Resolution of Pneumonia

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

A Model of Self-limited Acute Lung Injury by Unilateral Intra-bronchial Acid Instillation

Published on: August 30, 2019

Area of Science:

Pulmonology
Rheumatology
Critical Care Medicine

Background:

Connective tissue disorders (CTDs) frequently involve severe, life-threatening respiratory complications.
These acute respiratory events can affect all lung compartments and precipitate extrapulmonary organ involvement.
Lung involvement significantly contributes to morbidity and mortality in CTDs.

Purpose of the Study:

To outline the spectrum of acute respiratory events in connective tissue disorders (CTDs).
To emphasize the critical role of the lungs in CTD-related morbidity and mortality.
To highlight the need for specialized multidisciplinary approaches in managing these complex cases.

Main Methods:

Review of the literature on acute respiratory events in classic connective tissue disorders.
Analysis of respiratory manifestations across different lung compartments (airways, parenchyma, vasculature, pleura, muscles).
Consideration of associated factors including aspiration pneumonia, drug toxicity, and infections.

Main Results:

Acute respiratory events in CTDs range from subacute to catastrophic, often leading to respiratory failure.
These events can involve airways, lung parenchyma, capillaries, vessels, pleura, and ventilatory muscles.
Associated complications include aspiration pneumonia, drug toxicity, and infections secondary to immunosuppression.

Conclusions:

The lungs are a primary site for disease involvement, infection, and drug toxicity in CTDs.
Effective management necessitates specialized diagnostic and therapeutic strategies.
A multidisciplinary approach involving expert scientists is crucial for improving outcomes and potentially preventing lung disease in CTD patients.